| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Residual renal function is an important predictor of 1-year mortality in chronic kidney dialysis patients. In this study, we explored the biomarker of residual renal function (RRF) in peritoneal dialysis patients (PD). Sixteen PD patients (64 ± 11 years, men:10, women;6) were intended to this study. Blood and PD fluids sample were collected in peritoneal equilibration test (PET). Seventeen uremic toxins were quantified by LC-MS/MS. Relationship between plasma uremic toxin concentration and clinical parameters, RRF and InBody data was evaluated. From the results, plasma indoxyl sulfate (IS) and methylguanidine (MG) increased in PD patients in parallel with loss of RRF, but not peritoneal function. Furthermore, plasma concentrations of IS and MG were significantly correlate with body muscle mass. Our data suggested that plasma concentrations of IS and MG were increased with loss of RRF and they affect body muscle.
|
